What question did this study set out to answer?

This research aims to evaluate fistula calprotectin (FiCP) as a biomarker for inflammation and treatment response in perianal fistulizing Crohn's disease.

March 5, 2026

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease.

Key Points

This research aims to evaluate fistula calprotectin (FiCP) as a biomarker for inflammation and treatment response in perianal fistulizing Crohn's disease.
Evaluated the relationship between FiCP levels and local inflammatory activity.
Assessed the dynamic tracking of treatment response using FiCP as a biomarker.
FiCP levels correlated with local inflammation in perianal fistulizing Crohn's disease.
FiCP effectively monitored treatment response, indicating its potential clinical utility.

Abstract

FiCP represents a minimally invasive, tract-specific biomarker that mirrors local inflammatory activity and dynamically tracks treatment response in pfCD. Multicenter validation is warranted to define its clinical utility.

Bookmark

Cite This Study

Wang et al. (Tue,) studied this question.

synapsesocial.com/papers/69a91db5d6127c7a504c0cee https://doi.org/https://doi.org/10.1111/apt.70600

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark